Centiva Capital’s Kalaris Therapeutics KLRS Stock Holding History

Centiva Capital’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,996	Closed	-$99.7K	–	2700
2024 Q2	$99.7K	Buy	+5,996	New	+$106K	﹤0.01%	1855

Other funds holding KLRS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Centiva Capital's KLRS Position: Q3 2024 in Review

Centiva Capital sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 5,996 shares — an estimated $99.7K sold.

Centiva Capital first reported a position in KLRS in Q2 2024 and held it in 1 quarter. The position peaked at $99.7K in Q2 2024. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

Centiva Capital reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 5,996 Kalaris Therapeutics shares in Q3 2024, an estimated $99.7K.
Centiva Capital first reported a position in Kalaris Therapeutics in Q2 2024 and held it in 1 quarter.
Centiva Capital's Kalaris Therapeutics position peaked at $99.7K in Q2 2024.
59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.